School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
Proteomics Laboratory, Cathay Medical Research Institute, Cathay General Hospital, Taipei, Taiwan.
Aging (Albany NY). 2020 Nov 10;12(22):22700-22718. doi: 10.18632/aging.103890.
Malignant cancer may contain highly heterogeneous populations of cells, including stem-like cells which were resistant to chemotherapy agents, radiation, mechanical stress, and immune surveillance. The characterization of these specific subpopulations might be critical to develop novel strategy to remove malignant tumors. We selected and enriched small population of human melanoma A2058 cells by repetitive selection cycles (selection, restoration, and amplification). These subpopulation of melanoma cells persisted the characteristics of slower cell proliferation, enhanced drug-resistance, elevated percentage of side population as analyzed by Hoechst33342 exclusion, sphere formation, and xenograft tumor formation by small amount of tumor cells. The selected populations would be melanoma stem-like cells with high expression of stem cell markers and altered kinase activation. Microarray and bioinformatics analysis highlighted the high expression of angiopoietin-like 4 protein in drug-selected melanoma stem-like cells. Further validation by specific shRNA demonstrated the role of angiopoietin-like 4 protein in drug-selected subpopulation associated with enhanced drug-resistance, sphere formation, reduced kinase activation, tube-forming ability correlated with heparan-sulfate proteoglycans. Our finding would be applicable to explore the mechanism of melanoma stemness and use angiopoietin-like 4 as potential biomarkers to identify melanoma stem-like cells.
恶性肿瘤可能包含高度异质的细胞群体,包括对化疗药物、辐射、机械压力和免疫监视具有抗性的干细胞样细胞。这些特定亚群的特征分析可能对于开发新的策略来消除恶性肿瘤至关重要。我们通过重复选择循环(选择、恢复和扩增)从小部分人黑色素瘤 A2058 细胞中选择和富集小部分细胞。这些黑色素瘤细胞亚群保持着增殖速度较慢、耐药性增强、Hoechst33342 排除分析中侧群比例升高、小球形成以及少量肿瘤细胞形成异种移植肿瘤的特征。选择的群体将是具有高表达干细胞标记物和改变激酶激活的黑色素瘤干细胞样细胞。微阵列和生物信息学分析突出了血管生成素样蛋白 4 蛋白在药物选择的黑色素瘤干细胞样细胞中的高表达。通过特异性 shRNA 进一步验证表明,血管生成素样蛋白 4 蛋白在与耐药性增强、小球形成、激酶激活减少、与硫酸乙酰肝素蛋白聚糖相关的管形成能力相关的药物选择亚群中起作用。我们的发现可用于探索黑色素瘤干细胞特性的机制,并将血管生成素样蛋白 4 用作鉴定黑色素瘤干细胞样细胞的潜在生物标志物。